Metformin has been shown to directly induce antitumor effects by inhibiting the PI3K-Akt/mTOR and Ras-MAPK signaling pathways critical for cancer progression and indirectly by systemically reducing glucose and insulin metabolism to attenuate cancer cell growth (43, 44). Here, INS is linked to cancer.